Literature DB >> 33811118

Emerging Trends in Cancer Drug Discovery-From Drugging the "Undruggable" to Overcoming Resistance.

Joachim Rudolph1, Jeff Settleman2, Shiva Malek3.   

Abstract

Technology advancement and the courage to challenge dogma have been key elements that have continuously shifted druggability limits. We illustrate this notion with several recent cancer drug-discovery examples, while also giving an outlook on the opportunities offered by newer modalities such as chemically induced proximity and direct targeting of RNA. Treatment resistance is a major impediment to the goal of durable efficacy and cure, but the confluence of new biological insights, novel drug modalities, and drug combinations is predicted to enable transformative progress in this decade and beyond. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33811118     DOI: 10.1158/2159-8290.CD-21-0260

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  7 in total

1.  Covalent PROTACs: the best of both worlds?

Authors:  Neil P Grimster
Journal:  RSC Med Chem       Date:  2021-07-15

Review 2.  Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs.

Authors:  Ruth Nussinov; Mingzhen Zhang; Ryan Maloney; Yonglan Liu; Chung-Jung Tsai; Hyunbum Jang
Journal:  J Mol Biol       Date:  2022-04-01       Impact factor: 6.151

3.  Biology, technology and a bit of serendipity: an interview with Shiva Malek.

Authors:  Shiva Malek
Journal:  Dis Model Mech       Date:  2021-09-09       Impact factor: 5.758

Review 4.  USP28: Oncogene or Tumor Suppressor? A Unifying Paradigm for Squamous Cell Carcinoma.

Authors:  Cristian Prieto-Garcia; Ines Tomašković; Varun Jayeshkumar Shah; Ivan Dikic; Markus Diefenbacher
Journal:  Cells       Date:  2021-10-04       Impact factor: 6.600

5.  Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates.

Authors:  Ana Alcaraz-Sanabria; Esther Cabañas Morafraile; Gonzalo Fernández-Hinojal; Guillermo Velasco; Pedro Pérez-Segura; Atanasio Pandiella; Balázs Győrffy; Alberto Ocaña
Journal:  Front Immunol       Date:  2022-02-01       Impact factor: 7.561

Review 6.  Clinical considerations for the design of PROTACs in cancer.

Authors:  Cristina Nieto-Jiménez; Esther Cabañas Morafraile; Carlos Alonso-Moreno; Alberto Ocaña
Journal:  Mol Cancer       Date:  2022-03-07       Impact factor: 27.401

Review 7.  Targeting Protein Degradation Pathways in Tumors: Focusing on their Role in Hematological Malignancies.

Authors:  Anna Wolska-Washer; Piotr Smolewski
Journal:  Cancers (Basel)       Date:  2022-08-03       Impact factor: 6.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.